Exciva raises $59M Series B to fund Phase 2 test of Alzheimer’s agitation drug

Exciva has secured €51 million ($59 million) in a Series B raise to advance its candidate for a common behavioral symptom of Alzheimer’s disease into mid-stage development. The German biotech will use the proceeds to ...